Skip to main content

Table 1 Clinical characteristics of primary AML patients

From: Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia

 

Diagnose

Gender

Age (year)

FAB type

Cytogenetics

Molecular

WBC (*10^9/L)

HB (g/L)

PLT (*10^9/L)

patient 01

De novo

Female

69

M5b

46, XX

MLL-ELL, NRAS, KARS CSMD1, MECOM

68.87

87

29

patient 02

R/R

Female

74

M5

NA

FLT3-TID, NPM1

80.94

64

193

patient 03

De novo

Male

63

M2a

Complex karyotype

TP53, NARS

59.9

54

23

patient 04

De novo

Female

55

M5

46, XX

FLT3-TID, DNMT3A

165.11

78

115

patient 05

De novo

Female

44

M5

46, XX, del (8) (q22)

NA

12.79

66

10

patient 06

De novo

Male

34

M4

46, XY

FLT3-TID, DNMT3AIDH1

121.7

74

169

patient 07

De novo

Male

15

M5

Complex karyotype

FLT3, CBFβ-MYH11, NARS

31.6

79

22

patient 08

De novo

Female

50

M5

46, XX

FLT3-TID

24.57

70

105

patient 09

De novo

Female

43

M1

46, XX

WT1, FLT3, IDH2, NPM1

33.5

80

16

patient 10

De novo

Male

21

M4

47, XY, + mar

NA

28.17

45

4

patient 11

R/R

Female

44

M2a

NA

WT1, GATA2, CEBPA, KIT

11.45

52

15

patient 12

Refractory

Female

43

M4

46, XX, t (3; 3) (q21; q26)

NA

91.3

43

31